V A Miller

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 14:5731-4. 2008
  2. ncbi request reprint Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
    Marissa N Balak
    Human Oncology and Pathogenesis Program, Thoracic Oncology Service, Varmus Lab, Department of Pathology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 12:6494-501. 2006
  3. ncbi request reprint Initial clinical trial of a selective retinoid X receptor ligand, LGD1069
    V A Miller
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Cornell University Medical College, New York, NY 10021, USA
    J Clin Oncol 15:790-5. 1997
  4. ncbi request reprint Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer
    Vincent A Miller
    Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 21:2094-100. 2003
  5. ncbi request reprint Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities
    Vincent A Miller
    Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Room 1012 H Building, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 23:3288-93. 2005
  6. ncbi request reprint Optimizing therapy in previously treated non-small cell lung cancer
    Vincent A Miller
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 33:S25-31. 2006
  7. ncbi request reprint EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer
    Vincent A Miller
    Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol Nurs 24:27-33. 2008
  8. doi request reprint Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib
    Vincent A Miller
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard Building, Room 1012, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:1472-8. 2008
  9. ncbi request reprint Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer
    Vincent A Miller
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 22:1103-9. 2004
  10. ncbi request reprint Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer
    V A Miller
    Thoracic Oncology Service, Division of Solid Tumor Oncology, and Departments of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York, NY 10021, USA
    J Clin Oncol 18:1346-50. 2000

Detail Information

Publications68

  1. pmc Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 14:5731-4. 2008
    ..These mutations are predictive of poor prognosis in resected disease as well as resistance to treatment with erlotinib or gefitinib...
  2. ncbi request reprint Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
    Marissa N Balak
    Human Oncology and Pathogenesis Program, Thoracic Oncology Service, Varmus Lab, Department of Pathology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 12:6494-501. 2006
    ..We aimed to elucidate the frequency and nature of secondary EGFR mutations in patients with acquired resistance to TKI monotherapy...
  3. ncbi request reprint Initial clinical trial of a selective retinoid X receptor ligand, LGD1069
    V A Miller
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Cornell University Medical College, New York, NY 10021, USA
    J Clin Oncol 15:790-5. 1997
    ..Recently, LGD1069 was identified as a highly selective RXR agonist with low affinity for RARs. We undertook a dose-ranging study to examine the safety, clinical tolerance, and pharmacokinetics of LGD1069 in patients with advanced cancer...
  4. ncbi request reprint Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer
    Vincent A Miller
    Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 21:2094-100. 2003
    ..This pilot trial combined gefitinib with carboplatin and paclitaxel to define the toxicities of the combination and assess drug-drug interactions in untreated advanced NSCLC patients...
  5. ncbi request reprint Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities
    Vincent A Miller
    Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Room 1012 H Building, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 23:3288-93. 2005
    ....
  6. ncbi request reprint Optimizing therapy in previously treated non-small cell lung cancer
    Vincent A Miller
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 33:S25-31. 2006
    ....
  7. ncbi request reprint EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer
    Vincent A Miller
    Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol Nurs 24:27-33. 2008
    ..To discuss selected molecular targets and new clinical variables that can serve as both predictive and prognostic markers for outcome in patients with non-small cell lung cancer (NSCLC) treated with EGFR-TKIs...
  8. doi request reprint Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib
    Vincent A Miller
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard Building, Room 1012, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:1472-8. 2008
    ..We conducted this phase II trial to determine the efficacy of erlotinib in patients with bronchioloalveolar carcinoma (BAC) and adenocarcinoma, BAC subtype, and to determine molecular characteristics associated with response...
  9. ncbi request reprint Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer
    Vincent A Miller
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 22:1103-9. 2004
    ..Phase II trials suggested female sex and adenocarcinoma were associated with response. We undertook this analysis to identify additional clinical and pathologic features associated with sensitivity to gefitinib...
  10. ncbi request reprint Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer
    V A Miller
    Thoracic Oncology Service, Division of Solid Tumor Oncology, and Departments of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, New York, NY 10021, USA
    J Clin Oncol 18:1346-50. 2000
    ..We show that docetaxel (60 mg/m(2)) and vinorelbine (45 mg/m(2)) can be safely combined when given on an every 2-week schedule with filgrastim, with encouraging antitumor activity observed...
  11. ncbi request reprint Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer
    V A Miller
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer Chemother Pharmacol 40:415-8. 1997
    ..This phase II study assessed the antitumor activity of CQS while using an adaptive control pharmacokinetic modelling system to attain targeted plasma levels of this novel compound...
  12. ncbi request reprint Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer
    V A Miller
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Cornell University Medical College, NY, USA
    Ann Oncol 8:1269-71. 1997
    ..This phase II study was conducted to evaluate the efficacy and toxicity of tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer...
  13. ncbi request reprint Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
    F M Sirotnak
    Department of Medicine and Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 6:4885-92. 2000
    ..They also suggest significant clinical benefit from ZD1839 in combination with a variety of widely used cytotoxic agents...
  14. ncbi request reprint Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate
    L M Krug
    Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 6:3493-8. 2000
    ..These studies will also quantitate the expression of genes controlling internalization (RFC-1) and polyglutamylation of PDX in tumor cells as correlates of response...
  15. ncbi request reprint Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo
    F M Sirotnak
    Program of Molecular Pharmacology and Experimental Therapeutics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 6:3705-12. 2000
    ....
  16. ncbi request reprint High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib
    Antonio M P Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 103:2344-8. 2005
    ..Long- term outcome and patterns of disease recurrence after response have not been described...
  17. ncbi request reprint SCCRO expression correlates with invasive progression in bronchioloalveolar carcinoma
    Inderpal S Sarkaria
    Laboratory of Epithelial Cancer Biology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Thorac Surg 78:1734-41. 2004
    ..We hypothesized that SCCRO expression would correlate with invasive tumor phenotypes and worse survival in BAC...
  18. ncbi request reprint Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
    Gregory J Riely
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 12:839-44. 2006
    ..We undertook this study to explore the relationship between EGFR mutation type and clinical variables, including treatment with gefitinib and erlotinib...
  19. ncbi request reprint A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer
    Daniel T Milton
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 107:1034-41. 2006
    ..The objective of this study was to determine the tolerability and efficacy of high-dose erlotinib administered on a weekly schedule to patients with advanced nonsmall cell lung cancer (NSCLC)...
  20. pmc Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma
    James Bean
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 14:7519-25. 2008
    ..We aimed to identify additional second-site alterations associated with acquired resistance...
  21. ncbi request reprint Trastuzumab in the treatment of non-small cell lung cancer
    Christopher G Azzoli
    Department of Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 29:59-65. 2002
    ..Whether trastuzumab will show a clear benefit for patients with NSCLC, either alone or in combination with established chemotherapy, remains to be proven in phase III testing...
  22. ncbi request reprint Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas
    DuyKhanh Pham
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 24:1700-4. 2006
    ..Investigators have reported an association between EGFR mutations and the amount and duration of cigarette smoking, with the highest incidence of mutations seen in never smokers...
  23. ncbi request reprint Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung cancer
    Daniel T Milton
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 32:299-314. 2005
    ....
  24. ncbi request reprint The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index
    Yuhong She
    Program in Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 9:3773-8. 2003
    ..We subsequently investigated the extent to which ZD1839 might improve radiation therapy (RT) in similar animal models of human cancer within the limits of tolerance at a relevant organ site...
  25. ncbi request reprint Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer
    Daniel T Milton
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York, USA
    Cancer 110:599-605. 2007
    ..A phase 1 study was conducted of the combination of everolimus, an mTOR inhibitor, and gefitinib to determine a daily dose of everolimus with gefitinib in patients with advanced nonsmall-cell lung cancer (NSCLC)...
  26. ncbi request reprint Molecular on/off switch
    Daniel T Milton
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weil Medical College of Cornell University, New York, NY, USA
    J Clin Oncol 24:4940-2. 2006
  27. ncbi request reprint Use of erlotinib or gefitinib as initial therapy in advanced NSCLC
    Geoffrey R Oxnard
    Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncology (Williston Park) 24:392-9. 2010
    ..Currently active trials are referenced using their ClinicalTrials.gov identifier...
  28. ncbi request reprint Oral cisapride for the control of delayed vomiting following high-dose cisplatin
    B A Pizzo
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Cornell University Medical College, New York, New York, USA
    Support Care Cancer 7:44-6. 1999
    ..Since in prior trials among similar patients, placebo prevented delayed emesis in 11%, further study of cisapride and dose escalation for this indication are not recommended...
  29. ncbi request reprint Antitumor activity and tolerability of gefitinib in patients with non-small-cell lung cancer treated in an expanded access program
    Neelam T Shah
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6007, USA
    Clin Lung Cancer 5:182-6. 2003
    ..This series illustrates that the benefits of gefitinib are not limited to patients selected for clinical trial participation but can be generalized to the broader population of patients with NSCLC...
  30. ncbi request reprint Practical management of patients with non-small-cell lung cancer treated with gefitinib
    Neelam T Shah
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 23:165-74. 2005
    ..Many of the principles of management relevant to gefitinib are distinct from those with conventional cytotoxic drugs. To meet this need, we present practical guidelines on the use of gefitinib in patients with non-small-cell lung cancer...
  31. pmc EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression
    Allan R Li
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Mol Diagn 10:242-8. 2008
    ..Thus, these results indicate that EGFR amplification, preferentially of the mutant allele, often accompanies EGFR mutation, whereas EGFR immunohistochemical staining associates with amplification but cannot predict EGFR mutation status...
  32. ncbi request reprint Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer
    Naiyer A Rizvi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:639-43. 2008
    ..We undertook this trial to determine the maximum-tolerated dose (MTD) and single-agent activity of NAB-paclitaxel administered on a weekly basis to patients with stage IV non-small-cell lung cancer (NSCLC)...
  33. pmc High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer
    Jennifer L Clarke
    Department of Neurology and Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Neurooncol 99:283-6. 2010
    ..However, intermittent (pulsatile) high dose administration (1000-1500 mg/week) achieves a higher CSF concentration than standard dosing, and successfully controlled LM in this patient...
  34. ncbi request reprint Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma
    Lee M Krug
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 104:2149-55. 2005
    ..In the current study, the authors combined trastuzumab with weekly taxanes in an attempt to improve outcomes over standard chemotherapy in patients with advanced NSCLC...
  35. pmc Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib
    Maureen F Zakowski
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Arch Pathol Lab Med 133:470-7. 2009
    ..A subset of lung adenocarcinomas appears preferentially sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). EGFR-activating mutations and never smoking are associated with response to TKIs...
  36. pmc Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer
    Gregory J Riely
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10022, USA
    J Clin Oncol 27:264-70. 2009
    ..However, preclinical data support the hypothesis that intermittent administration of erlotinib before or after chemotherapy may improve efficacy. We tested this hypothesis in patients with advanced NSCLC...
  37. ncbi request reprint Pharmacokinetics and toxicity of weekly docetaxel in older patients
    Arti Hurria
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York 10021, USA
    Clin Cancer Res 12:6100-5. 2006
    ....
  38. ncbi request reprint A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis
    Robert J Downey
    Thoracic Services, Memorial Sloan Kettering Cancer Center, Division of Thoracic Surgery, 1275 York Avenue, New York, NY 10021, USA
    Lung Cancer 38:193-7. 2002
    ..The feasibility and potential benefit of combining surgery and chemotherapy in this setting are unclear. Therefore, we performed a prospective trial to test this therapeutic approach...
  39. ncbi request reprint A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors
    Christopher G Azzoli
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:2692-8. 2007
    ..This phase 1 study was designed to determine the maximum tolerated dose and toxicity of pralatrexate plus paclitaxel or docetaxel in patients with advanced cancer...
  40. pmc A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer
    Christopher G Azzoli
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Thorac Oncol 2:638-44. 2007
    ..We undertook this phase II study to measure postoperative drug delivery and toxicity of cisplatin plus docetaxel in patients with resected stage I-III non-small cell lung cancer...
  41. ncbi request reprint Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 13:5150-5. 2007
    ..In these patients, we sought to assess changes in tumor metabolism and size after stopping and restarting erlotinib or gefitinib and to determine the effect of adding everolimus...
  42. ncbi request reprint Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial
    Lee M Krug
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 103:2128-31. 2005
    ..The authors conducted a Phase II single-institution study of imatinib in patients with recurrent SCLC whose tumor specimens expressed c-kit protein...
  43. ncbi request reprint 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer
    Lee M Krug
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University New York, New York 10021, USA
    Clin Cancer Res 9:2072-8. 2003
    ..The recommended Phase II dose was 150 mg/m(2) i.v. every 2 weeks. Responses observed in patients with non-small cell lung cancer (NSCLC) in the Phase I trial prompted this Phase II trial...
  44. pmc Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    William Pao
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    PLoS Med 2:e73. 2005
    ..Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance...
  45. ncbi request reprint A phase I trial of perillyl alcohol in patients with advanced solid tumors
    Christopher G Azzoli
    Department of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Chemother Pharmacol 51:493-8. 2003
    ..This phase I trial was conducted to determine the optimal dose of perillyl alcohol...
  46. pmc KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
    William Pao
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    PLoS Med 2:e17. 2005
    ..Lung adenocarcinomas also harbor activating mutations in the downstream GTPase, KRAS, and mutations in EGFR and KRAS appear to be mutually exclusive...
  47. ncbi request reprint Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature
    Christopher G Azzoli
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Clin Oncol 26:247-51. 2003
    ..Patients predisposed to peripheral edema from some other cause may be at increased risk for developing severe peripheral edema with gemcitabine...
  48. ncbi request reprint Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin
    Lee M Krug
    Thoracic Oncology Service, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:6094-100. 2004
    ..A prior clinical study demonstrated the potent immunogenicity of fucosyl GM-1 derived from bovine thyroid gland, conjugated to keyhole limpet hemocyanin (KLH) and administered with QS-21 adjuvant...
  49. ncbi request reprint 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC)
    William Pao
    Department of Medicine and Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 62, New York, NY 10021, USA
    Semin Cancer Biol 14:33-40. 2004
    ..Whether EGFR is required for the maintenance of lung tumor survival is also discussed. Finally, strategies to identify predictors of response to gefitinib are explored...
  50. ncbi request reprint Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine
    Lee M Krug
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY, USA
    Lung Cancer 39:139-43. 2003
    ..In conclusion, bcl-2 and bax expression was similar in this population with advanced NSCLC to previously reported results for early stage disease, but did not predict response to vinorelbine plus docetaxel in this series...
  51. ncbi request reprint Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions
    William Pao
    Program in Cancer Biology and Genetics and the Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 23:2556-68. 2005
    ..Here, we present current knowledge about EGFR mutations in the context of clinical trials involving gefitinib and erlotinib in NSCLC...
  52. ncbi request reprint Phase I study of green tea extract in patients with advanced lung cancer
    Scott A Laurie
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10126, USA
    Cancer Chemother Pharmacol 55:33-8. 2005
    ..This trial was designed to determine the maximum tolerated dose (MTD) of green tea extract (GTE) in patients with advanced lung cancer...
  53. ncbi request reprint Pulmonary toxicity associated with erlotinib
    Vincent Liu
    Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Chest 132:1042-4. 2007
    ..Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for erlotinib pulmonary toxicity...
  54. ncbi request reprint Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma
    Michael I Ebright
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Thorac Surg 74:1640-6; discussion 1646-7. 2002
    ..This study determined the outcome of resected BAC in relationship to clinical and radiologic disease pattern, and pathologic features...
  55. ncbi request reprint A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors
    Matthew G Fury
    Division of Solid Tumor Oncology, Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Cancer Chemother Pharmacol 59:467-75. 2007
    ....
  56. ncbi request reprint Update on epidermal growth factor receptor mutations in non-small cell lung cancer
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 12:7232-41. 2006
    ..Although a tremendous amount of knowledge has been gained in the past 2 years, there remain a number of important epidemiologic, biological, and clinical questions...
  57. ncbi request reprint Targeting lethal minimal residual disease in small cell lung cancer
    Jyoti D Patel
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021, USA
    Semin Oncol 30:79-85. 2003
    ..This review will focus on the detection of minimal residual disease as well as strategies with which to treat it, including matrix metalloproteinase inhibitors, tyrosine kinase inhibitors, and vaccine therapy...
  58. pmc A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors
    Yelena Y Janjigian
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10065, USA
    Cancer Chemother Pharmacol 65:833-8. 2010
    ..We undertook this trial to determine the maximum-tolerated dose (MTD), toxicities and pharmacokinetic (PK) profile of SJG-136 in patients with an advanced solid tumor...
  59. ncbi request reprint Vascular endothelial growth factor trap in non small cell lung cancer
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College of Cornell University, New York, New York 10022, USA
    Clin Cancer Res 13:s4623-7. 2007
    ..Ongoing phase I trials are evaluating combinations of VEGF Trap with platinum-based doublets and single-agent docetaxel. The activity of single-agent VEGF Trap in NSCLC is being assessed in a multicenter phase II trial...
  60. ncbi request reprint The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease
    Scott A Laurie
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 95:119-26. 2002
    ..The objective of this study was to document the natural history of second lung carcinomas, common second tumors that arise in survivors of Hodgkin disease (HD)...
  61. ncbi request reprint Using patients as their own controls for cost evaluation of phase I clinical trials
    Eric J Sherman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:1308-14. 2004
    ..Our objective was to utilize a new approach, using patients as their own controls, to compare in a pilot study the costs of care for patients on phase I trials with those incurred for standard treatment...
  62. pmc Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
    David Jackman
    Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA
    J Clin Oncol 28:357-60. 2010
    ..These guidelines should minimize reporting of false-positive and false-negative activity in these clinical trials and would facilitate the identification of agents that truly overcome acquired resistance to gefitinib and erlotinib...
  63. ncbi request reprint Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?
    William Pao
    J Natl Cancer Inst 96:1117-9. 2004
  64. ncbi request reprint Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer
    Roy S Herbst
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 13:6175-81. 2007
    ..Based on supporting preclinical studies, we undertook a Phase II trial of pertuzumab in patients with recurrent non-small cell lung cancer (NSCLC)...
  65. ncbi request reprint Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
    David A Eberhard
    Department of Pathology, Genentech Inc, San Francisco, CA, USA
    J Clin Oncol 23:5900-9. 2005
    ..KRAS is frequently activated in NSCLC. The relationship of KRAS mutations to outcome after EGFR inhibitor treatment has not been described...
  66. ncbi request reprint TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
    Roy S Herbst
    University of Texas M D Anderson Cancer Center, Houston, USA
    J Clin Oncol 23:5892-9. 2005
    ..Erlotinib was combined with chemotherapy to determine if it could improve the outcome of patients with NSCLC...
  67. ncbi request reprint Erlotinib in lung cancer
    William Pao
    N Engl J Med 353:1739-41; author reply 1739-41. 2005
  68. doi request reprint EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations
    Jenifer L Marks
    J Thorac Oncol 3:805. 2008

Research Grants3

  1. Molecular Determinants of Acquired Erlotinib Resistance
    Vincent Miller; Fiscal Year: 2006
    ..abstract_text> ..
  2. A Phase 2 Trial of Dasatinib in Patients with NSCLC and Acquired Resistance to Er
    Vincent Miller; Fiscal Year: 2007
    ..The proposed work is a clinical trial to determine whether dasatinib is an effective treatment for patients with NSCLC and acquired resistance to erlotinib or gefitinib. [unreadable] [unreadable] [unreadable]..
  3. A Phase 2 Trial of Dasatinib in Patients with NSCLC and Acquired Resistance to Er
    Vincent Miller; Fiscal Year: 2008
    ..The proposed work is a clinical trial to determine whether dasatinib is an effective treatment for patients with NSCLC and acquired resistance to erlotinib or gefitinib. [unreadable] [unreadable] [unreadable]..